Beyond targeting the AAA microenvironment, vaccines against angiotensin II (Ang II)–AT1R pathway have shown preventive effects against AAA initiation in rodent models by blocking vascular growth and inflammation [50]. The gene discussed is AGT; the disease is triple-A syndrome.